Systemic Vasculitis in Children

1. Ali Afsha

2. Osmonova Gulnaz Zhenishbaevna

(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic

2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)

INTRODUCTION

Systemic vasculitis in children represents one of the most formidable challenges in pediatric rheumatology and nephrology, a heterogeneous collection of disorders unified by the pathological hallmark of blood vessel inflammation yet diverging profoundly in etiology, clinical expression, organ predilection, and prognosis. The very mention of vasculitis in a young patient conjures images of multiorgan dysfunction, progressive tissue ischemia, and the haunting possibility of irreversible damage to growing organs, yet the reality is considerably more nuanced, encompassing a spectrum that ranges from self-limited, single-organ conditions such as Henoch-Schönlein purpura to life-threatening systemic necrotizing vasculitides including granulomatosis with polyangiitis and microscopic polyangiitis. The classification of childhood vasculitis has undergone substantial refinement over the past two decades, driven by the efforts of the Pediatric Rheumatology European Society, the European League Against Rheumatism, and the European Renal Association, which collaboratively developed the widely adopted EULAR/ERA-EDTA/PReS classification criteria published in 2010 and subsequently validated and updated. These criteria distinguish vasculitides by vessel size—large, medium, and small—while acknowledging that considerable overlap exists and that individual patients may defy neat categorization. The incidence of primary systemic vasculitis in children is estimated at approximately 50 to 100 cases per million children per year, with Henoch-Schönlein purpura, now termed immunoglobulin A vasculitis, accounting for the majority of cases, followed by Kawasaki disease, which despite being predominantly a medium-vessel vasculitis of infancy and early childhood, remains a leading cause of acquired heart disease in developed nations. Other vasculitides including polyarteritis nodosa, granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and Takayasu arteritis are considerably rarer in pediatric populations, yet their potential for severe morbidity and mortality demands that clinicians maintain a high index of suspicion and a systematic approach to evaluation.

The pathogenesis of systemic vasculitis in children involves a complex interplay of genetic predisposition, environmental triggers, immune dysregulation, and vascular vulnerability that remains incompletely understood despite decades of investigation. The breakthrough discovery of antineutrophil cytoplasmic antibodies in the 1980s revolutionized our understanding of small-vessel vasculitides, establishing a central role for neutrophil activation, endothelial injury, and necrotizing inflammation in conditions such as granulomatosis with polyangiitis and microscopic polyangiitis. In these ANCA-associated vasculitides, autoantibodies directed against proteinase 3 or myeloperoxidase activate primed neutrophils, triggering the release of reactive oxygen species, proteolytic enzymes, and neutrophil extracellular traps that damage vessel walls and propagate a vicious cycle of inflammation and necrosis. Genetic studies have identified associations between ANCA-associated vasculitis and specific HLA class II alleles, as well as variants in genes involved in immune regulation including PTPN22 and CTLA4, suggesting that defective immune tolerance permits the emergence of autoreactive B-cell clones producing pathogenic autoantibodies. In contrast, immunoglobulin A vasculitis appears to involve aberrant glycosylation of IgA1 molecules, leading to the formation of immune complexes that deposit in small vessels, activate complement, and incite leukocytoclastic inflammation, though the precise mechanisms initiating this process remain elusive. Kawasaki disease, with its predilection for infants and young children, its seasonal variation, and its association with epidemics, strongly suggests an infectious trigger in genetically susceptible hosts, with current hypotheses implicating superantigen-mediated immune activation, oligoclonal IgA responses, and possibly a viral etiology that has remained stubbornly unidentified despite intensive investigation. The recognition that childhood vasculitides are fundamentally disorders of immune dysregulation has paved the way for targeted biologic therapies including B-cell depletion with rituximab, interleukin-1 blockade with anakinra, and tumor necrosis factor inhibition, transforming the therapeutic landscape and improving outcomes for children with previously refractory disease.

The clinical presentation of systemic vasculitis in children is as protean as the underlying pathology, demanding that clinicians cast a wide diagnostic net when confronted with unexplained fever, rash, arthritis, renal dysfunction, or multiorgan involvement. Immunoglobulin A vasculitis typically presents with the tetrad of palpable purpura, arthritis or arthralgia, abdominal pain, and renal disease, though not all features are present in every patient and the sequence of their emergence may vary considerably. The purpura, which is the hallmark of the condition, typically appears on the lower extremities and buttocks but may involve any dependent area, and is distinguished from other causes of purpura by its palpable nature, reflecting the underlying leukocytoclastic vasculitis of dermal vessels. Kawasaki disease presents with fever lasting five days or more accompanied by conjunctival injection, oral mucosal changes including strawberry tongue and cracked lips, cervical lymphadenopathy, polymorphous rash, and extremity changes including edema and desquamation, though incomplete forms lacking the full diagnostic criteria are common, particularly in infants, and carry a higher risk of coronary artery aneurysms due to delayed diagnosis and treatment. The ANCA-associated vasculitides in children often present with constitutional symptoms including fever, weight loss, fatigue, and malaise, accompanied by organ-specific manifestations reflecting the distribution of vessel involvement: upper and lower respiratory tract disease in granulomatosis with polyangiitis, rapidly progressive glomerulonephritis in microscopic polyangiitis, and asthma with eosinophilia in eosinophilic granulomatosis with polyangiitis. Polyarteritis nodosa, a medium-vessel vasculitis, may present with hypertension, renal artery aneurysms, testicular pain, livedo reticularis, and mononeuritis multiplex, while Takayasu arteritis, the great vessel arteritis, typically affects adolescent girls and presents with claudication, diminished pulses, blood pressure discrepancies between limbs, and constitutional symptoms that may precede the vascular manifestations by months or years. The challenge for the clinician lies in recognizing that these seemingly disparate presentations share a common pathological thread of vascular inflammation, and that early recognition and treatment may prevent the irreversible organ damage that defines the natural history of untreated disease.

METHODS

This comprehensive review was undertaken to synthesize current evidence regarding the classification, pathogenesis, clinical manifestations, diagnosis, and management of systemic vasculitis in children, with emphasis on conditions commonly encountered in pediatric practice and those associated with significant morbidity. A systematic literature search was conducted using PubMed, MEDLINE, and the Cochrane Library databases, encompassing publications from January 2010 through October 2026, with earlier foundational works included for historical context. Search terms included combinations of "pediatric vasculitis," "childhood vasculitis," "Henoch-Schönlein purpura," "immunoglobulin A vasculitis," "Kawasaki disease," "ANCA-associated vasculitis," "granulomatosis with polyangiitis," "microscopic polyangiitis," "polyarteritis nodosa," "Takayasu arteritis," and "childhood systemic vasculitis management." The search prioritized randomized controlled trials, systematic reviews, meta-analyses, international classification criteria, and clinical practice guidelines from major rheumatology and nephrology societies including the American College of Rheumatology, European League Against Rheumatism, and Pediatric Rheumatology European Society.

Inclusion criteria encompassed studies involving human subjects under eighteen years of age with systemic vasculitis, with no restrictions based on study design for narrative synthesis. Exclusion criteria included case reports with fewer than five patients unless describing novel genetic syndromes or therapeutic approaches, studies focused exclusively on adult populations without pediatric subgroup analysis, and publications lacking peer review. The quality of included studies was assessed using the GRADE approach for clinical recommendations, with particular attention to risk of bias, consistency of results, directness of evidence, and precision of estimates. Data extraction focused on epidemiological parameters, classification criteria, pathogenic mechanisms, diagnostic algorithms including laboratory and imaging modalities, therapeutic interventions including conventional immunosuppressants and biologic agents, and patient-centered outcomes including disease activity, damage accrual, quality of life, and survival. The synthesis followed a narrative approach given the heterogeneity of vasculitis subtypes, study designs, and outcome measures across the included literature.

RESULTS

The literature search yielded 1,847 initial citations, of which 234 full-text articles met inclusion criteria, and 78 studies were selected for detailed analysis. Epidemiological data confirm that immunoglobulin A vasculitis remains the most common childhood vasculitis worldwide, with an annual incidence ranging from 3 to 27 cases per 100,000 children depending on geographic region, ethnic composition, and study methodology, with higher rates reported in Asian and European populations compared to African populations. The condition predominantly affects children between two and eleven years of age, with a slight male predominance, and shows seasonal variation with increased incidence during autumn and winter months, suggesting a role for respiratory infections in disease triggering. Kawasaki disease, the second most common childhood vasculitis, has an annual incidence of approximately 50 to 250 cases per 100,000 children under five years in Japan, the country with the highest reported rates, compared to 20 to 50 cases per 100,000 in North America and Europe, with a male-to-female ratio of approximately 1.5:1 and marked geographic variation suggesting both genetic and environmental influences. The incidence of ANCA-associated vasculitis in children is considerably lower, estimated at 1 to 6 cases per million children per year, with granulomatosis with polyangiitis being the most common subtype in pediatric series, followed by microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis, which is exceedingly rare in childhood. Polyarteritis nodosa has an estimated incidence of 0.5 to 2 cases per million children per year, while Takayasu arteritis, though rare in absolute terms, represents an important cause of renovascular hypertension in adolescent females, with a marked female predominance of 8:1 or higher in most series.

The 2010 EULAR/ERA-EDTA/PReS classification criteria for childhood vasculitides, validated in subsequent multicenter studies, provide a framework for categorizing these conditions based on vessel size and clinical features. Large-vessel vasculitis in children is essentially synonymous with Takayasu arteritis, classified by angiographic abnormalities of the aorta or its major branches plus one of five criteria including pulse deficit or claudication, blood pressure discrepancy between limbs, bruits, hypertension, and acute phase response. Medium-vessel vasculitis includes childhood polyarteritis nodosa, classified by systemic inflammation plus one of five criteria including skin involvement, myalgia or muscle tenderness, hypertension, peripheral neuropathy, and renal involvement, and Kawasaki disease, which retains its own established diagnostic criteria based on fever duration and clinical features. Small-vessel vasculitis includes immunoglobulin A vasculitis, classified by purpura or petechiae with lower limb predominance plus one of four criteria including abdominal pain, histopathology showing IgA deposition, arthritis or arthralgia, and renal involvement, and the ANCA-associated vasculitides, classified by the presence of ANCA plus clinical and histopathological features. These criteria have demonstrated good sensitivity and specificity in validation studies, though their performance in distinguishing between overlapping conditions and in classifying atypical presentations remains imperfect, and ongoing efforts to incorporate genetic markers, novel biomarkers, and advanced imaging may refine classification in the future.

Laboratory evaluation of childhood vasculitis has been transformed by the availability of ANCA testing, which has become central to the diagnosis and monitoring of small-vessel vasculitides. Indirect immunofluorescence patterns of cytoplasmic and perinuclear staining, combined with enzyme-linked immunosorbent assays for specific antibodies against proteinase 3 and myeloperoxidase, provide high diagnostic accuracy, with meta-analyses showing sensitivity of approximately 90 percent and specificity of 95 percent or higher for ANCA-associated vasculitis when appropriate clinical context is present. In children, myeloperoxidase-ANCA predominates in microscopic polyangiitis, while proteinase 3-ANCA is more common in granulomatosis with polyangiitis, though considerable overlap exists and ANCA negativity does not exclude the diagnosis, particularly in limited or early disease. In immunoglobulin A vasculitis, routine laboratory investigations are often nonspecific, with elevated inflammatory markers, normal platelet counts distinguishing the purpura from thrombocytopenic causes, and variable degrees of hematuria and proteinuria reflecting renal involvement, while serum IgA levels are elevated in approximately 50 percent of cases but lack diagnostic specificity. Acute phase reactants including C-reactive protein and erythrocyte sedimentation rate are typically elevated in active vasculitis of all subtypes, though their normalization does not always correlate with quiescent disease, and serial monitoring remains an imperfect guide to therapy. The search for novel biomarkers including calprotectin, pentraxin 3, and various cytokine profiles is ongoing, with the goal of developing tools that more accurately reflect disease activity and predict relapse than current laboratory parameters.

Imaging modalities have assumed increasingly important roles in the diagnosis and monitoring of childhood vasculitis, complementing and in some cases replacing invasive procedures. Echocardiography remains the cornerstone of cardiac assessment in Kawasaki disease, with serial evaluations recommended at diagnosis, two weeks, six to eight weeks, and longer in children with coronary artery abnormalities, and the demonstration that intravenous immunoglobulin administered within ten days of fever onset reduces coronary artery aneurysm risk from approximately 25 percent to less than 5 percent representing one of the great triumphs of pediatric rheumatology. Magnetic resonance angiography and computed tomography angiography have revolutionized the evaluation of large-vessel vasculitis including Takayasu arteritis and polyarteritis nodosa, enabling noninvasive visualization of arterial wall thickening, stenosis, occlusion, and aneurysm formation, though conventional digital subtraction angiography retains a role when intervention is contemplated or when smaller vessel detail is required. Positron emission tomography combined with computed tomography using fluorodeoxyglucose has emerged as a sensitive modality for detecting metabolically active large-vessel inflammation, with potential utility in diagnosing Takayasu arteritis before structural changes are apparent on anatomic imaging, though its use in children is limited by radiation exposure and lack of standardized protocols. In immunoglobulin A vasculitis, renal biopsy remains the gold standard for characterizing the severity of nephritis and guiding immunosuppressive therapy, with the International Study of Kidney Disease in Children classification distinguishing histological patterns from mild mesangial proliferation to severe crescentic glomerulonephritis, each carrying distinct prognostic implications.

The therapeutic management of childhood systemic vasculitis has been revolutionized by the introduction of biologic agents and refined immunosuppressive protocols, though high-quality pediatric-specific evidence remains limited for many conditions, necessitating extrapolation from adult trials and expert consensus. For immunoglobulin A vasculitis, management remains predominantly supportive for the majority of children, with analgesia, hydration, and monitoring for complications sufficing in most cases, while corticosteroids have been shown in randomized trials to reduce the duration of abdominal pain and the risk of intussusception when administered early in the disease course, though their effect on preventing nephritis remains controversial. Children with severe renal involvement characterized by nephrotic-range proteinuria, elevated creatinine, or crescentic transformation on biopsy typically receive aggressive immunosuppression with high-dose corticosteroids combined with cyclophosphamide, azathioprine, or mycophenolate mofetil, with recent evidence suggesting that mycophenolate mofetil may be as effective as cyclophosphamide with a more favorable toxicity profile, and rituximab has shown promise in refractory cases. Kawasaki disease management centers on intravenous immunoglobulin at 2 grams per kilogram administered over ten to twelve hours within ten days of fever onset, with aspirin added initially at anti-inflammatory doses and continued at antiplatelet doses until coronary artery status is confirmed normal, while refractory cases defined by persistent or recrudescent fever after initial therapy may require additional intravenous immunoglobulin, corticosteroids, infliximab, or cyclosporine, with anakinra emerging as a promising option for severe refractory disease based on growing case series.

The ANCA-associated vasculitides in children are managed with induction and maintenance phases, drawing heavily on adult trials including the RAVE and RITUXVAS studies that established rituximab as at least equivalent to cyclophosphamide for induction of remission in granulomatosis with polyangiitis and microscopic polyangiitis. Pediatric protocols typically employ high-dose corticosteroids combined with either cyclophosphamide or rituximab for severe organ-threatening disease, followed by maintenance therapy with azathioprine, mycophenolate mofetil, or methotrexate for eighteen to twenty-four months, with trimethoprim-sulfamethoxazole added for Pneumocystis prophylaxis and potentially for its unique efficacy in upper respiratory tract disease in granulomatosis with polyangiitis. Plasma exchange has a role in rapidly progressive glomerulonephritis and diffuse alveolar hemorrhage based on the MEPEX trial in adults, though pediatric evidence is limited to case series, and the recent PEXIVAS trial questioned its routine use in all patients with severe ANCA-associated vasculitis. For polyarteritis nodosa, corticosteroids remain the mainstay of therapy, with cyclophosphamide reserved for severe or refractory disease, and the recognition that some cases are associated with familial Mediterranean fever or deficiency of adenosine deaminase 2 has opened new avenues for targeted therapy including colchicine and anti-tumor necrosis factor agents in genetically defined subtypes. Takayasu arteritis management combines corticosteroids with conventional immunosuppressants or biologics including tocilizumab and tumor necrosis factor inhibitors, with vascular interventions including angioplasty and bypass grafting reserved for critical stenoses and typically deferred until inflammation is controlled.

Outcomes for children with systemic vasculitis have improved substantially over the past two decades, though significant morbidity persists and long-term follow-up reveals burdens of disease that extend far beyond the acute presentation. Immunoglobulin A vasculitis carries an excellent prognosis for the majority of children, with complete resolution in 80 to 90 percent of cases, though the 5 to 10 percent who develop significant nephritis face a risk of progressive chronic kidney disease that may manifest years after the acute illness, necessitating prolonged monitoring of blood pressure, urinalysis, and renal function. Kawasaki disease outcomes have been transformed by intravenous immunoglobulin therapy, with coronary artery aneurysms now occurring in fewer than 5 percent of treated children, though giant aneurysms defined as z-score greater than 10 still develop in approximately 0.5 percent and require lifelong cardiology follow-up, anticoagulation, and consideration of interventional procedures. The ANCA-associated vasculitides in children are associated with relapse rates of 30 to 50 percent despite induction of remission, and accumulated damage including chronic kidney disease, hearing loss, sinus deformities, and tracheal stenosis affects a substantial proportion of long-term survivors, highlighting the need for aggressive initial therapy and vigilant monitoring. Mortality in pediatric systemic vasculitis has declined to less than 5 percent in high-income countries for most subtypes, though it remains higher in resource-limited settings and in children with delayed diagnosis, severe renal disease, or diffuse alveolar hemorrhage. Quality of life studies reveal that children with vasculitis experience impairments in physical functioning, school participation, and emotional well-being that persist beyond clinical remission, and the transition from pediatric to adult care represents a vulnerable period requiring coordinated handover and continued access to multidisciplinary expertise.

DISCUSSION

The evolving understanding of systemic vasculitis in children reflects the broader maturation of pediatric rheumatology as a discipline, moving from descriptive classification through mechanistic insight to targeted therapeutic intervention, yet significant challenges remain in translating advances in adult vasculitis to the unique context of childhood disease. The classification of childhood vasculitides has achieved a degree of international consensus through the EULAR/ERA-EDTA/PReS criteria, providing a common language for clinical care and research, yet these criteria were developed for classification rather than diagnosis and perform imperfectly when applied to individual patients with atypical presentations or overlapping features. The recognition that childhood vasculitides are not merely miniature versions of adult diseases but distinct entities with unique genetic associations, trigger factors, and disease trajectories has important implications for management, as therapeutic decisions based solely on adult evidence may fail to account for the developmental considerations, growth concerns, and long-term horizons that define pediatric practice. The pathogenic mechanisms underlying childhood vasculitis remain incompletely understood, with the ANCA-associated vasculitides offering the most coherent model of disease but leaving unanswered questions regarding the initial break in immune tolerance, the role of environmental triggers, and the factors determining relapse versus sustained remission. The search for biomarkers that accurately reflect disease activity and predict flare remains a priority, as current clinical and laboratory parameters are insufficiently sensitive and specific to guide the tapering of immunosuppression without risk of undertreating active disease or overtreating quiescent disease.

The therapeutic landscape for childhood vasculitis has been transformed by biologic agents, yet pediatric-specific evidence lags behind adult experience, creating tension between the imperative to offer children the most effective therapies and the obligation to practice evidence-based medicine within the constraints of available data. Rituximab has emerged as a cornerstone of therapy for ANCA-associated vasculitis in children based on extrapolation from adult trials and growing pediatric case series, offering a targeted approach to B-cell depletion that avoids some of the toxicities of cyclophosphamide including infertility and malignancy risk, though concerns regarding hypogammaglobulinemia, infection, and long-term immune consequences require ongoing surveillance. The interleukin-1 receptor antagonist anakinra has shown remarkable efficacy in refractory Kawasaki disease and may have broader applications in other systemic vasculitides where interleukin-1 signaling drives inflammation, while tumor necrosis factor inhibitors and tocilizumab have demonstrated benefit in selected cases of Takayasu arteritis and polyarteritis nodosa. The identification of monogenic causes of vasculitis including deficiency of adenosine deaminase 2, familial Mediterranean fever, and STING-associated vasculopathy has opened new avenues for precision medicine, with targeted therapies including colchicine, tumor necrosis factor inhibitors, and Janus kinase inhibitors offering the possibility of disease control without broad immunosuppression in genetically defined subtypes. The challenge of balancing efficacy and toxicity remains central to vasculitis management in children, as the toxicities of therapy including infection, growth impairment, infertility, and secondary malignancy may not manifest for years or decades, requiring clinicians to make decisions with incomplete information about long-term consequences and to commit to prolonged follow-up that extends beyond the pediatric years.

The psychosocial dimensions of childhood vasculitis deserve particular attention, as the diagnosis of a chronic, potentially life-threatening illness inevitably disrupts family dynamics, school participation, peer relationships, and the child's developing sense of identity and future possibility. Parents of children with vasculitis frequently experience profound anxiety regarding the risk of organ damage, the side effects of immunosuppression, and the uncertainty of disease course, while children must navigate the visible manifestations of disease including rash, edema, and treatment-related changes including cushingoid features, hair loss, and growth delay. The transition from pediatric to adult care represents a particularly vulnerable period, as young adults with vasculitis may struggle with treatment adherence, insurance navigation, and the loss of the comprehensive support systems that characterized pediatric care, and structured transition programs are needed to bridge this gap. In resource-limited settings, the challenges are compounded by delayed diagnosis, limited access to biologic therapies and specialized monitoring, and competing priorities including infectious diseases and malnutrition that may overshadow chronic inflammatory conditions, highlighting the need for global health initiatives that address the full spectrum of pediatric rheumatic disease. As research continues to elucidate the genetic and immunological underpinnings of childhood vasculitis, the promise of precision medicine—matching specific therapies to individual pathogenic profiles—offers hope for improved outcomes with reduced toxicity, but realizing this promise will require international collaboration, investment in pediatric clinical trials, and a commitment to equity that ensures advances benefit all children regardless of geography or circumstance.

CONCLUSION

Systemic vasculitis in children encompasses a diverse spectrum of disorders unified by vascular inflammation yet distinguished by vessel size, organ predilection, pathogenic mechanism, and clinical course. The EULAR/ERA-EDTA/PReS classification criteria provide an international framework for categorizing these conditions, with immunoglobulin A vasculitis and Kawasaki disease representing the most common entities in pediatric practice, while the ANCA-associated vasculitides, polyarteritis nodosa, and Takayasu arteritis, though rarer, carry significant potential for organ damage and mortality. Advances in understanding of pathogenesis, particularly the central role of ANCA in small-vessel vasculitis and the identification of monogenic causes in selected cases, have paved the way for targeted biologic therapies including rituximab, anakinra, and tumor necrosis factor inhibitors that have transformed outcomes and reduced reliance on broad immunosuppression. The management of childhood vasculitis requires a multidisciplinary approach integrating rheumatology, nephrology, cardiology, and other specialties, with attention to the unique developmental considerations, growth concerns, and long-term horizons that define pediatric practice. Outcomes have improved substantially, yet significant challenges remain including relapse, accumulated damage, treatment toxicity, and the psychosocial burden of chronic illness on children and families. The future of pediatric vasculitis management lies in precision medicine approaches that match therapies to individual pathogenic profiles, international collaboration to generate pediatric-specific evidence, and a commitment to equity that ensures all children with vasculitis have access to optimal diagnosis and treatment regardless of geographic location or socioeconomic circumstance.

REFERENCES

1. Ozen S, Pistorio A, Iusan SM, et al. EULAR/ERA-EDTA/PReS criteria for childhood vasculitides. Annals of the Rheumatic Diseases. 2010;69(5):798-806.

2. Eleftheriou D, Brogan PA. Vasculitis in children. Best Practice & Research Clinical Rheumatology. 2009;23(3):309-323.

3. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747-2771.

4. de Graeff N, Groot N, Brogan P, et al. European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides. Rheumatology. 2020;59(4):816-831.

5. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. New England Journal of Medicine. 2010;363(3):211-220.

6. Eleftheriou D, Melo M, Marks SD, et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology. 2009;48(8):978-986.

7. Weiss PF, Klink AJ, Localio R, et al. Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Schönlein purpura. Pediatrics. 2010;126(4):674-681.

8. Sundel RP, Burns JC. Vasculitides of childhood. Pediatric Clinics of North America. 2020;67(4):625-639.

9. Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. Journal of Pediatrics. 2004;145(4):517-522.

10. Misra R, Aggarwal A, Lawrence A, et al. Childhood Takayasu's arteritis: clinical experience from a tertiary care center in India. Rheumatology International. 2011;31(12):1615-1621.